Outcomes for Lymph Node-Positive Cutaneous Melanoma Over Two Decades

[1] Balch CM(2004)An evidence-based staging system for cutaneous melanoma CA Cancer J Clin 54 131-149

[2] Soong SJ(2009)Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 27 2916-2923

[3] Atkins MB(2008)Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 117-126

[4] Bottomley A(2001)High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2370-2380

[5] Coens C(2004)A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma Clin Cancer Res 10 1670-1677

[6] Suciu S(1996)Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 7-17

[7] Eggermont AM(2009)EANM-EORTC general recommendations for sentinel node diagnostics in melanoma Eur J Nucl Med Mol Imaging 36 1713-1742

[8] Suciu S(2008)The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2–pT3) Ann Surg Oncol 15 2223-2234

[9] Santinami M(2009)Sentinel lymph node biopsy for melanoma: indications and rationale Cancer Control 16 234-239

[10] Kirkwood JM(1995)Role of computed tomography in the staging of patients with local-regional metastases of melanoma J Clin Oncol 13 2104-2108

[1] Balch CM(2004)An evidence-based staging system for cutaneous melanoma CA Cancer J Clin 54 131-149

[2] Soong SJ(2009)Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 27 2916-2923

[3] Atkins MB(2008)Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 117-126

[4] Bottomley A(2001)High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2370-2380

[5] Coens C(2004)A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma Clin Cancer Res 10 1670-1677

[6] Suciu S(1996)Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 7-17

[7] Eggermont AM(2009)EANM-EORTC general recommendations for sentinel node diagnostics in melanoma Eur J Nucl Med Mol Imaging 36 1713-1742

[8] Suciu S(2008)The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2–pT3) Ann Surg Oncol 15 2223-2234

[9] Santinami M(2009)Sentinel lymph node biopsy for melanoma: indications and rationale Cancer Control 16 234-239

[10] Kirkwood JM(1995)Role of computed tomography in the staging of patients with local-regional metastases of melanoma J Clin Oncol 13 2104-2108